Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1D1 | P20393 | 4/20 | 0.59 |
| ▸ | MMP9 | P14780 | 4/20 | 0.46 |
| ▸ | MMP3 | P08254 | 3/20 | 0.46 |
| ▸ | MMP1 | P03956 | 2/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.46 |
| ▸ | ADAM9 | Q13443 | 2/20 | 0.46 |
| ▸ | BCL2 | P10415 | 1/20 | 0.45 |
| ▸ | BAD | Q92934 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | ACE | P12821 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5351382 | 0.85 | NPSR1 (0.48) | NR1D1MMP9MMP3MMP1ADAM17 | |
| SCHEMBL6370245 | 0.84 | NR1D1 (0.58) | NR1D1MMP9MMP3MMP1ADAM17 | |
| SCHEMBL28556786 | 0.84 | NR1D1 (0.68) | NR1D1BCL2BADGAAACE | |
| SCHEMBL29409301 | 0.84 | NR1D1 (0.68) | NR1D1BCL2BADGAAACE | |
| SCHEMBL12992250 | 0.83 | CHEK1 (0.46) | NR1D1MMP9MMP3MMP1ADAM17 | |
| SCHEMBL13545530 | 0.83 | CHEK1 (0.46) | NR1D1MMP9MMP3MMP1ADAM17 | |
| SCHEMBL10509244 | 0.83 | NR1D1 (0.67) | NR1D1BCL2BADGAAACE | |
| SCHEMBL16624032 | 0.82 | NR1D1 (0.56) | NR1D1MMP3BCL2BADGAA | |
| SCHEMBL19931777 | 0.80 | NR1D1 (0.63) | NR1D1BCL2BADACEPOLB | |
| SCHEMBL23343522 | 0.79 | NR1D1 (0.50) | NR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-08-18 | — | — | US | disclosed |
| EP-3053917-A1 | T-TYPE CALCIUM CHANNEL BLOCKER | Nissan Chemical Industries, Ltd. (JP) | 2016-08-10 | — | — | EP | disclosed |
| WO-2015103527-A1 | MODULATORS OF REV-ERB | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-07-09 | — | — | WO | disclosed |
| WO-2015103527-A1 | MODULATORS OF REV-ERB | THE SCRIPPS RESEARCH INSTITUTE (US) | 2015-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160237071-A1 | T-TYPE CALCIUM CHANNEL INHIBITOR | CACNA1I, CACNA1G, CACNA1H | NR1D1 415/4885MMP9 3710/4885MMP3 3528/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.